Unlike Lemon, Tate is a perimeter wideout who shows all the classic X-receiver traits, with potential to blend his game into a more diverse pre-snap option. He’s at his best when working against man ...

The GLP-1 revolution is reshaping obesity care, revealing how primary care economics and reimbursement gaps leave patients without needed support.

New bills, new enforcement actions, and a September deadline that turns every stalled bill into a live round. The post The ...

C3.ai, Inc. ("C3 AI," "C3," or the "Company") (NYSE: AI), the Enterprise AI application software company, today announced ...

Pursuit Reports Full Year and Fourth Quarter 2025 Results, Provides 2026 Guidance and Introduces Long-Term Financial Targets ...

Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. If you rely ...

Dividend Payout Policy -- Avista Corporation will target a payout ratio of 60% to 70%, compared to the prior 65% to 75% range ...

At the India AI Impact Summit 2026 last week, Galgotias University provided a shameful sideshow that gravely undermined India’s attempt to project itself as a serious player in the field of artificial ...

Circle will host a conference call to discuss the results for the fourth quarter and full fiscal year 2025 on February 25, 2026 at 8:00 am ET. Circle's Investor Relations website at ...

(CR) rate among all six efficacy evaluable patientsFavorable safety profile with no Grade >3 CRS or ICANSPrior investigator-initiated trial (IIT) reached median progression free survival (PFS) of 23.1 ...

Equillium (EQ) remains a 'Hold' as it advances EQ504 for ulcerative colitis, with phase 1 trial initiation targeted for mid-2026. Company's Multi-Cytokine Platform enables selective cytokine targeting ...